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Abstract
Background: ADAM22 is a member of the ADAM gene family, but the fact that it is expressed
only in the nervous systems makes it unique. ADAM22's sequence similarity to other ADAMs
suggests it to be an integrin binder and thus to have a role in cell-cell or cell-matrix interactions.
To elucidate the physiological functions of ADAM22, we employed gene targeting to generate
ADAM22 knockout mice.
Results: ADAM22-deficient mice were produced in a good accordance with the Mendelian ratio
and appeared normal at birth. After one week, severe ataxia was observed, and all homozygotes
died before weaning, probably due to convulsions. No major histological abnormalities were
detected in the cerebral cortex or cerebellum of the homozygous mutants; however, marked
hypomyelination of the peripheral nerves was observed.
Conclusion: The results of our study demonstrate that ADAM22 is closely involved in the correct
functioning of the nervous system. Further analysis of ADAM22 will provide clues to understanding
the mechanisms of human diseases such as epileptic seizures and peripheral neuropathy.
Background
ADAM (A Disintegrin And Metalloprotease) is a family of
membrane-spanning multi-domain proteins containing a
metalloproteinase-like domain and a disintegrin-like
domain. Currently, more than 30 ADAMs have been iden-
tified in mammals. Their biological activities implicate
ADAMs in fertilization, myogenesis and neurogenesis by
proteolysis and adhesion. Some types of ADAM are cata-
lytically active metalloproteases and shed the extracellular
domains of membrane-bound growth factors or receptors
[1,2]. For example, ADAM17 (TACE) has been shown to
cleave several substrates, including tumour necrosis factor
alpha[3,4], heparin-binding epidermal growth factor-like
growth factor [6,7] and transforming growth factor alpha
[8]. Studies of ADAM17-null mice have revealed that
ADAM17 is critical in embryogenesis and plays an
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essential role in the supply of growth factors [6,8]. ADAMs
are also involved in cell-cell or cell-matrix adhesion
through their interaction with integrins or syndecans.
More than 10 ADAMs have been shown to support
integrin-mediated cell adhesion in vitro [9]. It has been
reported that ADAM2-null and ADAM3-null male
mutants are infertile and their spermatozoa lack egg-bind-
ing abilities [10-12]. Both ADAM2 and ADAM3 are not
metalloproteases because they lack catalytic site sequences
in their metalloprotease domain. These studies clearly
showed that non-proteinase members of ADAMs also
have significant roles in vivo.
We have reported the findings of ADAM11, ADAM22 and
ADAM23 genes and their restricted expression in the
human and murine nervous systems [13-15]. Sequence
analysis suggests that they are not metalloproteases, since
they all lack a catalytic motif. It has been reported that
ADAM23 protein is localised to the cell surface [16], inter-
acts with alpha-v beta-3 integrin heterodimer [17] and the
disruption of ADAM23 gene in the mouse results in pre-
mature death associated with ataxia and tremor [18].
Although the cause of death in this mouse is unknown,
for these phenotypes, impaired cell-cell or cell-matrix
interactions in the nervous system caused by loss of
ADAM23 may be responsible. ADAM22 and ADAM23
share highly homologous sequences in their extracellular
domains. Especially, it is evident in their putative integrin
binding loop sequences, CR(E/D)AVN(E/D)CD, which is
located centre of the disintegrin domain. These findings
led us to hypothesize that ADAM22 is an integrin binder
and plays an important role in the nervous system, as does
ADAM23. To determine the physiological functions of
ADAM22, we generated and analysed Adam22 gene-tar-
geted mice.
Results
Generation of ADAM22-deficient mice
Mice carrying a targeted mutation in their Adam22 gene
were generated by homologous recombination (Fig. 1A).
Correct targeting events were confirmed by Southern blot
analysis (Fig. 1B). Since the termination codon was intro-
duced in exon 8 in the pro-protein domain, only the trun-
cated form of the ADAM22 protein would be synthesized
from this targeted allele. Because a pro-protein domain is
always removed in the mature functional ADAM-proteins
by the Furin-like proteases and is thought to be non-func-
tional itself, we considered that this truncated form of
ADAM22 protein has no function. Absence of mature
ADAM22 protein in homozygous mutants was confirmed
by Western blot analysis using the specific antibody,
which recognizes the cytoplasmic domain of the ADAM22
protein (Fig. 1C). Homozygous mutants showed no
noticeable defects at birth and were indistinguishable
from wild-type or heterozygous littermates during the first
week. At postnatal day 10 (P10), most of the homozygous
mutants were distinguishable by abnormalities such as
reduced body weight and uncoordinated movements of
their limbs. After P10, all homozygotes displayed severe
ataxia (Fig. 2) and began to die. To measure the survival
rate and body weight of each genotype precisely, we back-
crossed heterozygous male mutants to C57BL/6 females
more than 6 times. The resulting (N 6) heterozygous
males and females were intercrossed and the produced
offspring were analysed. The numbers of survivors of each
genotype every 5 days are shown in Table 1. At P10, the
ratio of each genotype was in close accordance with the
Mendelian ratio (20.5% +/+, 55.1% +/-, 24.4% -/- ; n =
78). This result shows that ADAM22 is not essential for
embryogenesis. At P10, the average body weight of
homozygous mutants was approximately half that of
wild-type and heterozygous littermates (Table 2).
Homozygous mutants died one by one after P10, and all
homozygotes died before P20. Of more than 100
homozygotes we have produced, none have survived
more than 25 days after birth. Meanwhile, heterozygous
mutants looked normal, were fertile, and survived for
more than one year without obvious defects.
Histopathology of ADAM22-deficient mice
We have reported the predominant expression of
ADAM22 mRNA in the human and mouse brain by
Northern blot analysis [13,14]. To determine the distribu-
tion of ADAM22 transcript in the adult mouse CNS
Table 1: Genotyping of the progeny of Adam22 heterozygous 
intercrosses.
Adam22 genotype
+/+ +/- -/- total
Day 10 16 43 19 78
Day 15 16 43 8 67
Day 20 16 43 0 59
From heterozygous intercrosses, 78 mice were produced. Numbers 
of mice in each genotype were counted on postnatal day 10, 15 and 
20. No homozygotes were survived more than postnatal day 20. +/+, 
wild-type; +/-, heterozygote; -/-, homozygote.
Table 2: Body weight of progeny at postnatal day 10.5
genotype body weight (g) no. of pups
+/+ 6.08 ± 0.61 9
+/– 5.84 ± 0.81 16
–/– 3.12 ± 0.48 7
+/+, wild-type; +/-, heterozygote; -/-, homozygote.BMC Neuroscience 2005, 6:33 http://www.biomedcentral.com/1471-2202/6/33
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Targeted mutation of Adam22 Figure 1
Targeted mutation of Adam22. (A) The genomic structure of the wild-type Adam22 allele (top), the targeting construct 
(middle) and the disrupted allele (bottom) are shown. ADAM22 expression was disrupted by the insertion of a termination 
codon and a PGKneo cassette into exon 8. An MC1/TK cassette at the end of the targeting vector allows for negative selec-
tion. The 3' probe represents the position of the external probe used for Southern blot analysis, and expected BamHI [B] frag-
ments are indicated by arrows. (B) Southern blot analysis of mouse genomic DNA. The expected DNA fragments for the wild-
type allele and disrupted allele are 7.5-kb and 2.5-kb, respectively. +/+, wild-type; +/-, heterozygote; -/-, homozygote. (C) 
Western blot analysis of ADAM22 expression in the mouse cerebellum. Absence of ADAM22 protein in the Adam22 (-/-) 
mutant cerebellum was shown using anti-ADAM22-cp (cytoplasmic domain) polyclonal antibody.BMC Neuroscience 2005, 6:33 http://www.biomedcentral.com/1471-2202/6/33
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precisely,  in situ hybridisation analysis was performed
using 35S-labeled RNA probe. As shown in Fig. 3,
ADAM22 mRNA was expressed throughout the adult
mouse CNS. Strong signal was detected in the cerebellar
granule cells and hippocampal formation. In the spinal
cord, hybridisation signal was restricted to the grey mat-
ter. The distribution of ADAM22 transcripts in the CNS
was quite similar with that of ADAM11, whose neuronal
expression has been reported [19]. These results suggest
that the ADAM22 mRNA expression is neuronal in the
mouse CNS.
Based on the mRNA distribution pattern, we performed
immunohistopathological analysis of the cerebellum and
hippocampus extensively. Despite the high level of
expression of ADAM22 mRNAs in the cerebellar granule
Uncoordinated movements in the Adam22 (-/-) mice at postnatal day 18 (P18) Figure 2
Uncoordinated movements in the Adam22 (-/-) mice at postnatal day 18 (P18). (A) Adam22 (-/-) mice were smaller 
than their wild-type (+/+) littermates. (B, C) Adam22 (-/-) mice at P18 were unable to support themselves on their hindlimbs.
Neuronal ADAM22 mRNA expression in the CNS Figure 3
Neuronal ADAM22 mRNA expression in the CNS. To determine the ADAM22 mRNA distribution, in situ hybridisation 
analysis using 35S-labeled probe was performed. Coronal (A, B) and sagittal (C, D) sections of the mouse brain and spinal cord 
(E) were shown. Using the antisense probe (A, C), strong signals were obtained, especially in the hippocampus and the cerebel-
lum, while no signals was detected by the sense probe (B, D). In the spinal cord, autoradiograms of ADAM22 mRNA was 
detected in the grey matter (E).BMC Neuroscience 2005, 6:33 http://www.biomedcentral.com/1471-2202/6/33
Page 5 of 12
(page number not for citation purposes)
cells, granule cell layer was normally formed and Purkinje
cell morphology (calbindin-staining) of the mutant
mouse looked intact (Figs. 4A–D). Hippocampal forma-
tion was also normally formed (Figs. 4I–J). These results
suggest that neuronal cell migration was not impaired in
the mutant mouse. Myelin-formation detected by MBP
(myelin basic protein) staining of the mutant in the cere-
bellum (Fig. 4H) and spinal cord (Fig. 4L) was also indis-
tinguishable with the wild-type littermate (Figs. 4G,K). In
summary, we could not find any signs of abnormalities in
the mutant mouse brain by the light microscopic
examination.
Next, the spinal cord and peripheral nerves of each geno-
type were analysed by toluidine blue stain, which reveals
myelin formation. Surprisingly, lack of myelin or thin
myelin was observed in the sciatic nerves (Fig. 5B) and
trigeminal nerves (Fig. 5D) in homozygous mutants.
Because no lesions were observed in the spinal cord (Fig.
5F), it was suggested that Schwann cell specific myelina-
tion defect occurred in the homozygous mice. To analyse
the state of myelinating Schwann cells and axons, electron
microscopic (EM) analysis of the sciatic nerve was per-
formed (Fig. 6). Schwann cells formed thin or no myelin
in the homozygous mutant (Fig. 6B). In contrast, hetero-
zygous mice showed complete myelination (Fig. 6A).
Morphology of the axons looked normal in each geno-
type. Immunohistochemical analysis of the sciatic nerve
showed that increased number of nuclei (Fig. 7B) and
reduced staining of MBP (Fig. 7D) were remarkable in the
homozygous mutant. The Schwann cell marker, S100
staining signal was intensely observed in the homozygote
as well as wild-type (Figs. 7E, F). These results suggest that
proliferation of the Schwann cells was not impaired but
differentiation is severely delayed in the ADAM22-defi-
cient mice.
Novel ADAM22 transcript variants isolated from the 
peripheral nervous system
In the case of human ADAM22, isolation of five splicing
variants and existence of two terminating exons have been
reported [13,20,21]. However, the latter terminating exon
(exon 31) of the mouse species has not been identified
yet. To isolate the long form of mouse ADAM22 tran-
scripts, at first, we sought the mouse genome by BLAST
homology search. Search results showed that the mouse
genome contig NT_039297 contained most of the mouse
Adam22 gene. In this contig sequence, we found putative
exons 30 and 31, those sequences were quite similar to
human ADAM22 isoform 1 (GenBank # NM_021723). To
confirm existence of transcripts, we designed primers on
the putative exon 31 and performed RT-PCR using mouse
cerebellum mRNA as a template. TA-cloning of the ampli-
fied fragments and sequencing analysis showed that 5 of
8 clones were type 1 isoform (G01), 2 clones were type 3
Normal neurodevelopment in the CNS of ADAM22-deficient  mice Figure 4
Normal neurodevelopment in the CNS of ADAM22-
deficient mice. Sagittal sections of the cerebellum from 
wild-type mice (A, C, E, G) and homozygous mutants (B, D, 
F, H) at postnatal day 13 were stained for calbindin (C and D; 
green) or MBP (G and H; green), and were counterstained 
with DAPI (A, B, E, F; blue). Significant abnormalities were 
not observed in the homozygotes. Hippocampal neurons 
were stained by anti-Neu N antibody (I and J). Spinal myelin 
was analysed by MBP staining (K and L). These analyses 
showed no obvious differences between homozygotes (J, L) 
and wild-type littermates (I, K). Bar: (A, B, E, F) 100 µm, (K, 
L) 250 µm.BMC Neuroscience 2005, 6:33 http://www.biomedcentral.com/1471-2202/6/33
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isoform (G03) and 1 clone (G08) contained a novel exon
between exons 29 and 30. Next, we performed RT-PCR
analysis of mRNAs purified from several adult mouse tis-
sues, such as the spinal cord, dorsal root ganglion (DRG),
sciatic nerve and cultured primary Schwann cells. Interest-
ingly, multiple DNA fragments were amplified from each
tissue (Fig. 8), and length of major fragments in each lane
was different. For example, length of major amplified PCR
fragments from the sciatic nerve (Fig. 8A, lane 5) and cul-
tured Schwann cells (lane 6) were almost identical, and
were shorter than those from other tissues. In contrast,
major fragments from the DRG (lane 4) were longer than
others. We performed TA-cloning and sequencing to ana-
lyse exon organization of the amplified transcripts (Fig.
8C). Forty seven clones were isolated in total and were
classified in 16 independent clones (G01 – G23).
Comparison with the genomic sequence revealed the
existence of 8 novel exons (exons 27S, 27L, 29.1, 29.3,
29.5, 29.7, 30 and 31). These novel exons were flanked by
well-defined introns that obey the GT-AG rule. Exon
organization of each clone was shown in Fig. 8C. Charac-
teristic feature of ADAM22 transcripts is tissue specific
insertion or skipping of exons. Because the number of
nucleotides of exons 26, 27, 27L, 29.3, 29.5 and 29.7 is a
multiple of 3, insertion or skipping of these exons will not
change the downstream reading frame. Known peptide
motives were not found in the newly isolated sequences.
This RT-PCR analysis is summarized as follows: ADAM22
transcripts were roughly subdivided in 3 groups, CNS-
form (containing exon 27), DRG-form (containing exon
27L) and Schwann-cell-form (skipping exon 26 and 27).
From these results, we concluded that ADAM22 is
expressed in a cell-type specific manner, and plays an
essential role in myelinogenesis in the PNS.
Hypomyelination of peripheral nerves in ADAM22-deficient mice Figure 5
Hypomyelination of peripheral nerves in ADAM22-deficient mice. Epon embedded semithin cross-sections of the sci-
atic nerves (A, B), the trigeminal nerves (C, D) and the spinal cord [lateral funiculus] (E, F) of the indicated genotypes at post-
natal day 10 were stained with toluidine blue. Note that the ADAM22-deficient mouse shows thin myelin or lack of myelin in 
the peripheral nerve fibres (B, D), but the spinal myelinated fibres are intact (F).BMC Neuroscience 2005, 6:33 http://www.biomedcentral.com/1471-2202/6/33
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Discussion
In the present study, we examined the function of
ADAM22 by generating mice that lacked the Adam22
gene. ADAM22-deficient mice exhibited severe ataxia and
premature death. In contrast, heterozygous mutants were
healthy, fertile and survived more than 1 year without
obvious abnormalities. The cause of death in the
homozygous mutants is not clear; however, it is likely to
be due to multiple seizures. This is because convulsive sei-
zures were occasionally observed in homozygotes, after
which the suffered mice appeared exhausted and, in most
cases, died on the next day. It is known that cortical dys-
plasia resulting from aberrant brain development causes
seizure syndrome [22]. For example, mice lacking the neu-
ron-specific activator of cyclin 5, p35, exhibit seizures and
a severe neuronal migration defect [23]. Because ADAM22
protein is expressed on the cell surface and is likely to be
involved in cell-cell or cell-matrix interactions, we
hypothesized that depletion of ADAM22 would generate
aberrant neuronal migration. Histochemical analysis was
performed to verify this hypothesis. However, no marked
abnormalities were observed in the mutant mouse brain,
ruling out a critical role for ADAM22 in neuronal migra-
tion. Another possible explanation is that the premature
death in first 2 weeks of life is caused by the dysfunction
of the autonomic nervous system. Especially, nerves
which control the breathing would be very important,
because the respiration system undergoes significant mat-
uration in the first 2–3 weeks after birth. For example, the
myelin-deficient (MD) rat, which carries a point mutation
in the proteolipid protein (PLP) gene, exhibits ataxia,
tremor, dysmyelination and dies at approximately postna-
tal day 21. In MD rat, early death is caused by the dysfunc-
tion of the brain stem which is essential for autonomic
control of respiration during hypoxia [24]. Further study
is needed to verify the cause of death in ADAM22-defi-
cient mice.
Another interesting phenotype observed in ADAM22-
deficient mice was hypomyelinogenesis.
Histopathological analysis revealed marked hypomyeli-
nation in the sciatic and trigeminal nerves. However,
myelin formation in the spinal cord and the brain was
normal. It was therefore evident that hypomyelinogenesis
occurred specifically in the peripheral nerves in the knock-
out mice, suggesting Schwann cell dysfunction. In the
mutant sciatic nerve, the density of pro-myelinating
Schwann cells (S100-positive, MBP-negative) was mark-
Electron microscopic analysis of sciatic nerves Figure 6
Electron microscopic analysis of sciatic nerves. Electron micrographs of the sciatic nerves from Adam22 +/- (A) and 
Adam22 -/- (B) mice at postnatal day 10 are shown. In the heterozygote (A), thick myelin was formed, while no myelin was 
formed in the ADAM22-deficient mouse (B). The axons looked normal in each genotype.BMC Neuroscience 2005, 6:33 http://www.biomedcentral.com/1471-2202/6/33
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edly higher than that seen in heterozygotes. Higher pro-
myelinating Schwann cell density and marked delay in
myelin formation indicate that ADAM22 plays an impor-
tant role in Schwann cell differentiation, but not in
proliferation.
Investigations on why hypomyelinogenesis occurred in
ADAM22-deficient mice centre on integrin. This is
because several ADAMs have been shown to interact with
integrins via disintegrin domains [9], and it has been sug-
gested that alpha-6 beta-1 integrin on the Schwann cell
plays an important role in myelin formation [25]. In addi-
tion, laminin-2 is a key player in peripheral myelin forma-
tion, because laminin-2 deficiency causes dysmyelination
in mice and humans, and its receptors, alpha-6 beta-1
integrin and dystroglycan, are also shown to be deeply
involved in myelin formation [26,27]. The conditional
knockout studies of beta-1 integrin and laminin gamma-
1 in Schwann cell suggested that both laminin-2 and
integrins are essential for segregation of large bundles of
axons in the early stage of myelin formation [25,28]. In
contrast, the phenotype seen in the ADAM22-deficient
mice was quite different: for example, unsorted bundles of
axons were not seen in nerves and roots. We assume that
ADAM22 partially modulates integrin-mediated signals or
is involved at a later stage of myelin formation.
Conclusion
In summary, we generated ADAM22-deficient mice and
proved that ADAM22 plays an essential role in both the
CNS and the PNS. The results of this study suggest that
ADAM22 is involved in human diseases such as epilepsy
and peripheral neuropathy. The human ADAM22 gene is
relatively large, at 300 kb in length, and is comprised of
more than 30 exons. It is assigned on 7q21, where several
chromosomal aberrations that are accompanied by neu-
rological disorders have been identified [29,30]. Further
detailed molecular function analysis of ADAM22 may
lead to progress in uncovering the mechanisms that
underlie certain human neurological diseases.
Marked delay in differentiation of the mutant Schwann cells Figure 7
Marked delay in differentiation of the mutant Schwann cells. Transverse sections of the sciatic nerves of the indicated 
genotypes at postnatal day 13 were stained for MBP (C and D; green) or S100 (E and F; red), and were counterstained with 
DAPI (A, B; blue). In the mutant sciatic nerve, density of DAPI-signals were greatly increased (B) compared with those of the 
wild-type (A). Bar: (A, B) = 50 µm.BMC Neuroscience 2005, 6:33 http://www.biomedcentral.com/1471-2202/6/33
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Adam22 gene structure and tissue specific transcripts Figure 8
Adam22 gene structure and tissue specific transcripts. (A) RT-PCR analysis. Amplified DNA fragments were analysed 
by 1 % agarose gel electrophoresis. Lanes 1. 100 bp DNA ladder; 2. cerebellum; 3. spinal cord; 4. dorsal root ganglion; 5. sciatic 
nerve; 6. cultured Schwann cells; 7. distilled water (B) Exon organization of the mouse Adam22 gene is illustrated. Boxes indi-
cate exons. The G01 transcript (orthologous to the human ADAM22 isoform 1 transcript) is composed of grey boxes. Boxes 
in black indicate non-coding region. (C) Summary of the isolated clones. The nucleotide sequence data have been deposited 
with the DDBJ/EMBL/GenBank Data Libraries under the accession numbers described in the table. (D) Number of clones iso-
lated from each tissue is summarized. Cb; cerebellum, Sp; spinal cord, DRG; dorsal root ganglion, SN; sciatic nerve, cSC; cul-
tured Schwann cells.
1
A
24 25 26 27 28 29 29.1 29.3 29.5 29.7
27L 29T
27S
ISH04F
ISH04R
30 31T
1234567
2.0
1.5
0.6
Fig.8
B
C
D
DDBJ exon
clone ID Accession 25 26 27 28 29 29.1 29.3 29.5 29.7 30 31T alias name
ADAM22-G01 AB179842 25 26 27 28 29 xxxx 30 31T 22g
ADAM22-G03 AB179843 25 26 x 28 29 xxxx 30 31T 22g(D27)
ADAM22-G06 AB179844 25 xx28 29 xxxx 30 31T 22g(D26D27)
ADAM22-G07 AB179845 25 xx28 29 x 29.3 xx 30 31T 22g(D26D27)+29.3
ADAM22-G08 AB179846 25 26 x 28 29 x 29.3 xx 30 31T 22g(D27)+29.3
ADAM22-G09 AB179847 25 26 27 28 29 x 29.3 xx 30 31T 22g+29.3
ADAM22-G10 AB179858 25 26 27 28 29 29.1 xxx 30 31T 22g+29.1
ADAM22-G11 AB179857 25 26 x 28 29 xx 29.5 29.7 30 31T 22g(D27)+29.5+29.7
ADAM22-G12 AB179859 25 26 27 28 29 x 29.3 29.5 x 30 31T 22g+29.3+29.5
ADAM22-G17 AB179848 25 26 27L 28 29 x 29.3 x 29.7 30 31T 22g[27L]+29.3+29.7
ADAM22-G18 AB179849 25 x 27L 28 29 xxxx 30 31T 22g(D26)[27L]
ADAM22-G19 AB179850 25 26 27L 28 29 xx 29.5 x 30 31T 22g[27L]+29.5
ADAM22-G20 AB179851 25 26 27L 28 29 xxxx 30 31T 22g[27L]
ADAM22-G21 AB179860 25 x 27S 28 29 xxxx 30 31T 22g(D26)[27S]
ADAM22-G22 AB179852 25 26 x 28 29 xxx 29.7 30 31T 22g(D27)+29.7
ADAM22-G23 AB179861 x x x 28 29 xxxx 30 31T 22g(D25D26D27)
length 91 18 108 101 67 58 111 87 30 124 STOP
(bp) 195(27L)
62(27S)
RT-PCR Number of isolated clones
clone ID (bp) Cb Sp DRG SN cSC total
ADAM22-G01 620 520007
ADAM22-G03 512 210317
ADAM22-G06 494 00037 1 0
ADAM22-G07 605 000213
ADAM22-G08 623 100012
ADAM22-G09 731 030003
ADAM22-G10 678 010001
ADAM22-G11 629 010001
ADAM22-G12 737 010001
ADAM22-G17 848 006006
ADAM22-G18 689 001001
ADAM22-G19 794 001001
ADAM22-G20 707 001001
ADAM22-G21 556 001001
ADAM22-G22 542 001001
ADAM22-G23 403 000011
89 1 1 8 1 1 4 7BMC Neuroscience 2005, 6:33 http://www.biomedcentral.com/1471-2202/6/33
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Methods
Construction of an Adam22 gene-targeting vector
The 18-kb genomic DNA fragments covering exons 5, 6, 7,
8 and 9 of the Adam22 gene were amplified from C57BL/
6 genomic DNA by PCR using Expand Hi-Fidelity enzyme
mix (Roche Diagnostics) and primers designed for each
exon. To generate a mutation in the mouse Adam22 gene,
we inserted the PGKneo cassette into exon 8 of the
Adam22 gene. The final targeting construct consisted of a
10.5-kb genomic DNA fragment that was interrupted by
the insertion of the PGKneo cassette and contained a
MC1/TK cassette as a negative selection marker against
random integration [5].
Generation of Adam22 deficient mice
The linearised targeting vector was electroporated into
TT2 embryonic stem (ES) cells [31]. Homologous recom-
binants were selected by PCR. The extracted genomic DNA
from each clone was amplified using the forward primer
AGN2: 5'-GCCTGCTTGCCGAATATCATGGTGGAAAAT-3'
in the PGKneo cassette, and the reverse primer MFP065R:
5'-ACTATTTCTGTGATGAGGGCACAGCATC-3' outside
the targeting vector. Homologous recombined DNA was
efficiently amplified by 35 cycles of the following amplifi-
cation steps (94°C-30 s and 68°C-5 min). The targeting
efficiency of this construct was about 4%. Correctly tar-
geted ES clones were injected into fertilized ICR mouse
eggs at the eight-cell stage. The resulting male chimeras
were mated with C57BL/6N females, and heterozygous
male and female mice were interbred to generate
homozygous mice. The ataxic phenotypes of homozygous
mice were observed in two independent lines.
Southern blot analysis
Mouse genomic DNA used for Southern blot analysis was
extracted from the liver of each genotype. BamHI-digested
genomic DNA was probed with the [32P]-labelled 0.4-kb
SpeI-BamHI genomic fragment, which is located between
exons 8 and 9.
Antibody production
His-tagged and MBP-fused recombinant protein contain-
ing cytoplasmic domain (cp) of human ADAM22 isoform
1 (position: 756–906, 151 amino acids in length) were
produced in E. coli. His-tagged ADAM22-cp protein was
purified in denatured condition using Ni-NTA resin (Qia-
gen GmbH) and dialysed in PBS. Precipitated protein was
recovered and was mixed with Freund's complete
adjuvant (Invitrogen), then, the mixture was used for
immunization of rabbits. The antiserum raised against the
His-tagged ADAM22-cp protein was incubated with MBP-
fused ADAM22-cp protein coupled to Affi-Gel 10 beads
(Bio-Rad). Beads with bound antibodies were washed in
PBS, and the bound antibodies were eluted with 100 mM
glycine, pH 3.0, and neutralized immediately. Using the
affinity purified antibody, both human and mouse
ADAM22 proteins were detected by Western blot analysis.
However, unfortunately the antibody was not suitable for
immunohistochemical analysis of mouse tissues.
Western blot analysis
The absence of ADAM22 protein in the Adam22 -/- mice
was confirmed by Western blot analysis. Briefly, the cere-
bellum was isolated from a P14.5 mouse of each genotype
and homogenized with a Polytron homogenizer in cell
lysis buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1%
NP-40, Complete protease inhibitors [Roche Diagnos-
tics]). After removal of cell debris by centrifugation, the
supernatant was separated on 10% SDS-PAGE, and trans-
ferred to a nitrocellulose membrane. The blot was then
incubated with polyclonal antibody against the cytoplas-
mic domain of ADAM22 (at 1:1,000). Bound antibodies
were visualized with horseradish peroxidase-labelled sec-
ond antibody and a ECL-plus chemiluminescence detec-
tion system (Amersham Biosciences Corp.).
Primary Schwann cell culture
Primary Schwann cells were prepared from 4-month-old
C57BL/6 mice according to Manent's protocol [32] with
minor modifications. Briefly, sciatic nerves were removed
and incubated for 7 days in the pre-treatment medium,
which consisted of D-MEM (high glucose) supplemented
with 10% FCS, 50 mg/ml gentamicin (Invitrogen Corp.),
2.5 µg/ml fungizone (Invitrogen Corp.), 2 µM forskolin
(EMD Biosciences Inc.) and 10 ng/ml recombinant hereg-
ulin-beta1 (R&D Systems). For dissociation, cultured sci-
atic nerves were cut into pieces and incubated at 37°C for
3 hours in Opti-MEM medium (Invitrogen Corp.)
containing 130 U/ml collagenase type I (Invitrogen
Corp.) and 0.4 U/ml dispase II (Roche Diagnostics). Dis-
sociated cells were resuspended in the pre-treatment
medium and plated on Poly-D-Lysine/Laminin coated
plate (BD Biosciences). The purity of the cultured
Schwann cells, as determined by indirect immunofluores-
cence analysis, approached 90 %.
RT-PCR analysis
Adult C57BL/6 male mice were used in this study. Total
RNAs purified from the cerebellum, spinal cord, sciatic
nerve, DRG and cultured Schwann cells using TRIzol (Inv-
itrogen Corp.) and RNeasy kit (Qiagen GmbH) were ana-
lysed by RT-PCR using SuperScript II and random primer
(Invitrogen Corp.), and PCR amplification (40 cycles;
94°C-30 s, 60°C-30 s and 68°C-5 min) with Expand Hi-
Fidelity DNA polymerase (Roche Diagnostics) and
ADAM22-specific primers. To detect splicing variants in
the cytoplasmic domain, a forward primer was placed just
upstream of the transmembrane domain and a reverse
primer was set on the terminating exon. The primers used
in this study were as follows. ISH04-forward: 5'-AACAG-BMC Neuroscience 2005, 6:33 http://www.biomedcentral.com/1471-2202/6/33
Page 11 of 12
(page number not for citation purposes)
GCACTGGACAGGGGCTGAC-3' and ISH04-reverse: 5'-
AATGGATGTCTCCCATAGCCTGGC-3'.
Histopathology
Mice were anesthetized with ethyl ether. Whole-body per-
fusion by 2% paraformaldehyde-glutaraldehyde solution
followed by heparin-included saline was performed. Sci-
atic nerves, trigeminal nerves, brain and spinal cord were
removed and fixed in 10% neutral-buffered formalin. The
spinal cord and other nerve blocks were washed and post-
fixed with 2% osmium tetroxide, and were dehydrated in
ethanol and equilibrated in Epon. Epon embedded semi-
thin sections were stained with toluidine blue and were
subjected to light microscopic examination. For electron
microscopic analysis, thin sections were cut using an
ultramicrotome, stained with 1.5% uranylacetate in 50%
ethanol and 0.8% lead citrate, and analysed using electron
microscope. All procedures were conducted according to
the Eisai Animal Care Committee's guidelines.
Immunohistochemistry
Frozen sections were rinsed in 0.1% Triton X-100/PBS at
room temperature for 1 hour, and were blocked in
BLOCKACE solution (Dai-nippon). The following anti-
bodies were incubated overnight in 0.1% BLOCKACE at
4°C:
monoclonal mouse anti-calbindin 28 K (Sigma, 1:200);
monoclonal mouse anti-MBP (SMI-99, Sternberger Mon-
oclonals Inc., 1:50); monoclonal mouse anti-Neu N
(CHEMICON, 1:100); rabbit anti-S100 polyclonal
(DAKO, 1:200). Nuclei were counterstained with 1 µg/ml
DAPI (Sigma). MBP staining was performed after micro-
wave epitope retrieval in 10 mmol/L citrate buffer (pH 6).
Sections were incubated for 1 hour with secondary anti-
bodies: Cy3-labeled donkey anti-rabbit IgG (Jackson
Immuno Research, 1:200), FITC-labelled donkey anti-
mouse IgG (Jackson Immuno Research, 1:200). Sections
were photographed with an Olympus microscope (Olym-
pus IX71) equipped with a high-resolution CCD camera.
RNA in situ hybridisation
In situ hybridisation on frozen sections were carried out
using 35S-labelled RNA probes. Briefly, 610 bp of mouse
ADAM22 cDNA (position: 1351–1960 from initiating
ATG) was cloned into the pBluescript II SK(+) or the
pBluescript II KS(+) vector. Using these plasmids as tem-
plates, sense and antisense labelled RNA probes were gen-
erated by T7 RNA polymerase and [α 35S]UTP. Frozen
brain and spinal cord from 2 month-old C57BL/6 female
mice were used in this analysis. Pretreatment, hybridisa-
tion, RNase treatment and washing was carried out fol-
lowing the protocol described in the literature [33].
Dehydrated slides were attached to imaging plates for 48
hours and the autoradiograms were analysed using a Bio-
Image Analyser (BAS3000, Fuji Photo Film).
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